+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Herpes Zoster (Shingles) - Pipeline Review, H1 2020

  • ID: 5017502
  • Drug Pipelines
  • March 2020
  • Region: Global
  • 69 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Akshaya Bio Inc
  • CanSino Biologics Inc
  • CPL Biologicals Pvt Ltd
  • GC Pharma
  • GeneOne Life Science Inc
  • GlaxoSmithKline Plc
  • MORE
Herpes Zoster (Shingles) - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Herpes Zoster (Shingles) - Pipeline Review, H1 2020, provides an overview of the Herpes Zoster (Shingles) (Infectious Disease) pipeline landscape.

Shingles (herpes zoster) is a painful, blistering skin rash. It is caused by the varicella-zoster virus. Symptoms may include fever and chills, headache, joint pain and swollen glands. The predisposing factors include age and weakened immune system. Treatment includes antihistamines and pain relievers.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Herpes Zoster (Shingles) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Herpes Zoster (Shingles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 2, 8, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Herpes Zoster (Shingles) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Herpes Zoster (Shingles) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Herpes Zoster (Shingles) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Herpes Zoster (Shingles) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Herpes Zoster (Shingles) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Herpes Zoster (Shingles) (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Herpes Zoster (Shingles) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Akshaya Bio Inc
  • CanSino Biologics Inc
  • CPL Biologicals Pvt Ltd
  • GC Pharma
  • GeneOne Life Science Inc
  • GlaxoSmithKline Plc
  • MORE
  • Introduction
  • Report Coverage
  • Herpes Zoster (Shingles) - Overview
  • Herpes Zoster (Shingles) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Herpes Zoster (Shingles) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Herpes Zoster (Shingles) - Companies Involved in Therapeutics Development
  • Akshaya Bio Inc
  • Beijing Minhai Biotechnology Co Ltd
  • CanSino Biologics Inc
  • Changchun Bcht Biotechnology Co Ltd
  • CPL Biologicals Pvt Ltd
  • DongKoo Bio & Pharma Co Ltd
  • GC Pharma
  • GeneOne Life Science Inc
  • GlaxoSmithKline Plc
  • NAL Pharmaceuticals Ltd
  • NanoViricides Inc
  • Shulov Innovative Science Ltd
  • Vaccitech Ltd
  • Vapogenix Inc
  • XBiotech Inc
  • Herpes Zoster (Shingles) - Drug Profiles
  • B-1006 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CRV-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CSB-016 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drug for Shingles - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GLS-5100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • herpes zoster vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • herpes zoster vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • herpes zoster vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • interferon alfa-2b - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Monoclonal Antibodies for Shingles - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NAL-3220 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NVHHV-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Inflammatory Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • varicella zoster vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VTP-400 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ZEP-3 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Herpes Zoster (Shingles) - Dormant Projects
  • Herpes Zoster (Shingles) - Discontinued Products
  • Herpes Zoster (Shingles) - Product Development Milestones
  • Featured News & Press Releases
  • Mar 10, 2020: First QS-21 royalty payment due to Agenus is triggered
  • Jan 30, 2020: NanoViricides confirms it has been working on a treatment for the novel Wuhan Coronavirus
  • Jan 09, 2020: NanoViricides successfully completes required genetic toxicology testing of lead Drug candidate NV-HHV-101
  • Jan 07, 2020: NanoViricides has initiated genetic toxicology testing required for an IND for its drug candidate
  • Dec 06, 2019: NanoViricides annual meeting of shareholders to be held on Saturday, December 7th, 2019 at the Sheraton Hotel, Stamford, CT
  • Dec 03, 2019: NanoViricides founder Dr. Diwan provides $2,000,000 loan commitment to the company
  • Dec 02, 2019: NanoViricides has initiated required safety pharmacology assessment of lead drug candidate towards IND
  • Nov 19, 2019: NanoViricides files quarterly report for period ending September 30, 2019 - HerpeCide drug candidate ind enabling studies update, progressing towards clinical trials
  • Oct 31, 2019: NanoViricides initiates required dermal sensitization and ocular irritation testing of lead drug candidate towards IND
  • Oct 09, 2019: NanoViricides has initiated bio-analytical studies as part of IND-enabling safety and toxicology studies of lead candidate NV-HHV-101
  • Oct 03, 2019: NanoViricides is creating nanomedicines to develop antiviral therapies to combat shingles and herpes viruses
  • Sep 26, 2019: Curevo Vaccine announces interim results of phase I clinical trial of CRV-101
  • Aug 26, 2019: NanoViricides advancing rapidly towards first IND
  • Aug 05, 2019: NanoViricides reports its first drug candidate is on track with GLP safety/toxicology studies toward human clinical trials
  • Jul 10, 2019: Shingles vaccine safely prevents outbreaks among stem cell transplant patients
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development for Herpes Zoster (Shingles), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Herpes Zoster (Shingles) - Pipeline by Akshaya Bio Inc, H1 2020
  • Herpes Zoster (Shingles) - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2020
  • Herpes Zoster (Shingles) - Pipeline by CanSino Biologics Inc, H1 2020
  • Herpes Zoster (Shingles) - Pipeline by Changchun Bcht Biotechnology Co Ltd, H1 2020
  • Herpes Zoster (Shingles) - Pipeline by CPL Biologicals Pvt Ltd, H1 2020
  • Herpes Zoster (Shingles) - Pipeline by DongKoo Bio & Pharma Co Ltd, H1 2020
  • Herpes Zoster (Shingles) - Pipeline by GC Pharma, H1 2020
  • Herpes Zoster (Shingles) - Pipeline by GeneOne Life Science Inc, H1 2020
  • Herpes Zoster (Shingles) - Pipeline by GlaxoSmithKline Plc, H1 2020
  • Herpes Zoster (Shingles) - Pipeline by NAL Pharmaceuticals Ltd, H1 2020
  • Herpes Zoster (Shingles) - Pipeline by NanoViricides Inc, H1 2020
  • Herpes Zoster (Shingles) - Pipeline by Shulov Innovative Science Ltd, H1 2020
  • Herpes Zoster (Shingles) - Pipeline by Vaccitech Ltd, H1 2020
  • Herpes Zoster (Shingles) - Pipeline by Vapogenix Inc, H1 2020
  • Herpes Zoster (Shingles) - Pipeline by XBiotech Inc, H1 2020
  • Herpes Zoster (Shingles) - Dormant Projects, H1 2020
  • Herpes Zoster (Shingles) - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Herpes Zoster (Shingles), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3
  • Akshaya Bio Inc
  • Beijing Minhai Biotechnology Co Ltd
  • CanSino Biologics Inc
  • Changchun Bcht Biotechnology Co Ltd
  • CPL Biologicals Pvt Ltd
  • DongKoo Bio & Pharma Co Ltd
  • GC Pharma
  • GeneOne Life Science Inc
  • GlaxoSmithKline Plc
  • NAL Pharmaceuticals Ltd
  • NanoViricides Inc
  • Shulov Innovative Science Ltd
  • Vaccitech Ltd
  • Vapogenix Inc
  • XBiotech Inc
Note: Product cover images may vary from those shown
Adroll
adroll